Q-omics provides the consensus-scored SIX5 profile across patient tissues and cancer cell-line models. SIX5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SIX5 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, SIX5 RNA expression shows 19,906 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, HNSC, and ACC as cancer lineages where SIX5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIX5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIX5 survival associations across molecular data types. SIX5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIX5 RNA expression–survival associations across cancer types. High SIX5 expression shows unfavorable associations in LUAD, ACC, COAD, LGG, KIRC and LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SIX5 RNA expression.
This table summarizes SIX5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SIX5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIX5 shows lower tumor expression in KICH, UCEC and THCA and higher tumor expression in HNSC, LIHC and COAD. The HNSC box plot shows higher SIX5 RNA expression in tumor versus normal tissue (log2 FC = +0.871, t-test p < 0.001).
This table shows molecular features associated with SIX5 in patient tissues and cancer cell lines. In patient samples, SIX5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SIX5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
